natgillin/translations-raw huggingface dataset:
Patienterne fik Clopidogrel (300 mg loading dose efterfulgt af 75 mg daglig, n=1.752) eller placebo (n=1.739) begge i kombination med ASA (150-325 mg som loading dose, herefter
Patients received Clopidogrel (300 mg loading dose, followed by 75 mg/day, n = 1752) or placebo (n = 1,739), both in combination with ASA (150 to
Patienterne fik clopidogrel (300 mg loading dose efterfulgt af 75 mg daglig, n=1752) eller placebo (n=1739) begge i kombination med ASA (150 - 325 mg som loading dose, herefter 75 -
Patients received clopidogrel (300 mg loading dose, followed by 75 mg/day, n=1,752) or placebo (n=1,739), both in combination with ASA (150 to
Patienterne fik clopidogrel (300 mg støddosis efterfulgt af 75 mg daglig, n=1.752) plus ASA eller ASA alene (n=1.739) (150-325 mg som støddosis, herefter 75-162 mg daglig), et fibrinolytisk middel samt  når det var hensigtsmæssigt  heparin.
Patients received clopidogrel (300 mg loading dose, followed by 75 mg/day, n=1,752) plus ASA or ASA alone (n=1,739), (150 to 325 mg as a loading dose, followed by 75 to 162 mg/day), a fibrinolytic agent and, when appropriate, heparin.
Patienterne fik Coagadex til behandling af spontane blødninger, der opstod i løbet af behandlingsperioden, eller som forebyggelse af blødning under operation.
Patients in the study received Coagadex to treat any spontaneous bleeding that occurred during the treatment period or to prevent bleeding during surgery.
Patienterne fik dels taget røntgen af brystkassen eller CT-scanning, dels en SPECT-
The patients underwent a chest X-ray or a CT scan as well as a SPECT scan using radiolabelled NeoSpect.
Patienterne fik den lavere styrke (70 mg/2.800 IE) af FOSAVANCE (n=350) eller FOSAMAX (alendronat) 70 mg (n=332) én gang ugentligt; yderligere D- vitamin tilskud var ikke tilladt.
Patients received the lower strength (70 mg/2,800 IU) of FOSAVANCE (n=350) or FOSAMAX (alendronate) 70 mg (n=332) once a week; additional vitamin D supplements were prohibited.
Patienterne fik den lavere styrke (70 mg/2.800 IE) af VANTAVO (n=350) eller FOSAMAX (alendronat) 70 mg (n=332) én gang ugentligt; yderligere D-vitamin tilskud var ikke tilladt.
Patients received the lower strength (70 mg/2800 IU) of VANTAVO (n=350) or FOSAMAX (alendronate) 70 mg (n=332) once a week; additional vitamin D supplements were prohibited.
Patienterne fik doser på op til 80 mg 3 gange dagligt og efter 3 år var 68% af 133 patienter i behandling med Revatio 80 mg 3 gange dagligt.
Doses up to 80 mg TID were administered and after 3 years 68 % of 133 patients on study treatment were receiving Revatio 80 mg TID.
Patienterne fik drotrecogin alfa (aktiveret) indenfor 48 timer efter, at det første sepsis- inducerede organsvigt var indtrådt.
Patients received drotrecogin alfa (activated) within 48 hours of onset of the first sepsis- induced organ dysfunction.
Patienterne fik emtricitabin 200 mg en gang daglig og tenofovir DF 300 mg en gang daglig.
Patients were administered emtricitabine 200 mg once daily and tenofovir DF 300 mg once daily.
Patienterne fik en 96 timers Xigris infusion med en konstant hastighed på 24 g/kg/time (n=850) eller placebo (n=840).
Patients were given a 96-hour constant rate infusion of Xigris at 24 g/kg/hr (n=850) or placebo (n=840).
Patienterne fik en Benlysta-dosis på 10 mg/kg, som blev administreret intravenøst over en periode på 1 time på dag 0, 14, 28 og herefter hver 28. dag i 52 uger.
Patients received Benlysta 10 mg/kg intravenously over a 1-hour period on Days 0, 14, 28, and then every 28 days for 52 weeks.
Patienterne fik enten alirocumab i en dosis på 150 mg hver 2. uge eller placebo, som tillæg til deres eksisterende lipidmodificerende behandling.
Patients received either alirocumab at a dose of 150 mg Q2W or placebo in addition to their existing lipid-modifying therapy.
Patienterne fik enten ikke antiretroviral behandling med et CD4+ celletal på > 500 celler/mm3, eller de havde virologisk supprimeret hiv-1 med et CD4+ celletal > 200 celler/mm3.
Subjects were either not on antiretroviral therapy with a CD4+ cell count >500 cells/mm3 or had virologically suppressed HIV-1 with a CD4+ cell count >200 cells/mm3.
Patienterne fik enten lumacaftor/ivacaftor (n=62) eller placebo (n=63) i tillæg til deres ordinerede CF- behandlinger.
Patients received either lumacaftor/ivacaftor (n=62) or placebo (n=63) in addition to their prescribed CF therapies.
Patienterne fik enten Macugen (0,3 mg, 1 mg eller 3 mg) eller en skininjektion.
The patients were given either Macugen (0.3 mg, 1 mg or 3 mg) or a ‘sham’ injection.
Patienterne fik enten placebo eller Rebif (44 mikrogram givet en eller tre gange om ugen) i to år.
Patients received either placebo or Rebif (44 micrograms given once or three times a week) for two years.
Patienterne fik enten Raxone, 900 mg dagligt, eller placebo, i en periode på 24 uger (6 måneder).
Patients received either 900 mg/day Raxone or placebo for a period of 24 weeks (6 months).
Patienterne fik enten Remsima eller Remicade som tillægsbehandling til methotrexat i 30 uger.
Patients received either Remsima or Remicade in addition to methotrexate for 30 weeks.
Patienterne fik enten zoledronsyre 4 mg eller placebo hver fjerde uge i et år.
Patients received either zoledronic acid 4 mg or placebo every four weeks for one year.
Patienterne fik et Ozurdex-implantat eller fik en "skinbehandling", hvor en applikator blev presset mod øjet, uden at der rent faktisk blev injiceret noget.
The patients were given an Ozurdex implant or they received a ‘sham’ treatment where an applicator was pressed against their eye but nothing was actually injected.
Patienterne fik et Ozurdex-implantat på enten 700 eller 350 mikrogram, eller de fik en skinbehandling.
Patients were given either a 700 microgram or a 350 microgram implant of Ozurdex or they received a sham treatment.
Patienterne fik foretaget en knoglebiopsi af hoftebenskammen, enten som del af en kontrolgruppe eller før og efter eksponering for asfotase alfa:
Patients underwent biopsy of the trans-iliac bone crest either as part of a control group or before and after exposure to asfotase alfa:
Patienterne fik forskellige doser af Revestive eller standardbehandling i 12 uger.
Patients received different doses of Revestive or standard treatment for 12 weeks.
Patienterne fik først lov til at reducere eller afbryde deres baseline ITP-behandling under studiets åbne fase, og 53 % (8/15) af patienterne kunne reducere (n = 1) eller afbryde (n = 7) baseline ITP- behandlingen, hovedsagelig kortikosteroider, uden behov for redningsmedicin.
Subjects were permitted to reduce or discontinue baseline ITP therapy only during the open-label phase of the study and 53% (8/15) of subjects were able to reduce (n=1) or discontinue (n=7) baseline ITP therapy, mainly corticosteroids, without needing rescue therapy.
Patienterne fik Hizentra en gang om ugen i 28 uger.
The patients received Hizentra every week for 28 weeks.
Patienterne fik Humira 0,8 mg/kg hver anden uge (op til 40 mg), 0,4 mg/kg hver anden uge (op til 20 mg) eller methotrexat 0,1- 0,4 mg/kg ugentlig (op til 25 mg).
Patients received Humira 0.8 mg/kg eow (up to 40 mg), 0.4 mg/kg eow (up to 20 mg), or methotrexate 0.1- 0.4 mg/kg weekly (up to 25 mg).
Patienterne fik i gennemsnit mellem 8,4 – 8,6 behandlinger ud af 9 mulige på tværs af alle behandlingsarme i det første år.
Patients received a mean of between 8.4-8.6 treatments out of possible 9 total across all treatment arms in the first year.
Patienterne fik ikke tilladelse til at modtage supplerende levodopa eller catechol-O- methyl transferase (COMT) -hæmmere.
Patients were not allowed to receive supplemental levodopa or catechol-O-methyl transferase (COMT) inhibitors.
Patienterne fik initialt avanafil 100 mg og kunne på ethvert tidspunkt under forsøge anmode om at få deres dosis af avanafil sat op til 200 mg eller sat ned til 50 mg, afhængigt af deres individuelle respons på behandlingen.
Patients were initially assigned to avanafil 100 mg and at any point during the trial, they could request to have their dose of avanafil increased to 200 mg or decreased to 50 mg based on their individual response to treatment.
Patienterne fik kemoterapien på dag ét af en 3-ugers cyklus og fik derefter én dosis af Grastofil næste dag og dagligt i op til 14 dage.
Patients were given the chemotherapy on day 1 of a three-week cycle, and then received one dose of Grastofil the next day and daily for up to 14 days.
Patienterne fik lav-dosis acetylsalicylsyre forud for randomisering og gennem begge de 2 CABG- undersøgelser.
Patients received low-dose acetylsalicylic acid prior to randomization and throughout the two CABG surgery studies.
Patienterne fik lov til at fortsætte behandlingen med methotrexat i løbet af undersøgelsen.
Patients were allowed to continue treatment with methotrexate during the study.
Patienterne fik meningokokvaccination inden behandling med Soliris eller passende antibiotisk profylakse i 2 uger efter vaccination.
Patients received meningococcal vaccination prior to receipt of Soliris or received prophylactic treatment with appropriate antibiotics until 2 weeks after vaccination.
Patienterne fik Oncaspar som monoterapi eller i kombination med flere midler i kemoterapi.
Patients received Oncaspar as a single agent or in combination with multi-agent chemotherapy.
Patienterne fik Onivyde eller 5- fluorouracil plus leucovorin eller de tre lægemidler i kombination.
Patients were given Onivyde or 5-fluorouracil plus leucovorin, or the three medicines in combination.
Patienterne fik op til 6 injektioner med en måneds mellemrum og blev fulgt i op til tre år efter den første injektion.
Patients were given up to 6 injections at 1-month intervals and were followed up for 3 years from the first injection.
Patienterne fik placebo og en startdosis på 7,5 mg methotrexat og derefter dosisøgning op til uge 12 til en maksimum-dosis på 25 mg eller en startdosis på 80 mg Humira efterfulgt af 40 mg hver anden uge (med start en uge efter den første dosis) i 16 uger.
Patients received placebo, an initial dose of MTX 7.5 mg and thereafter dose increases up to Week 12, with a maximum dose of 25 mg or an initial dose of 80 mg Humira followed by 40 mg every other week (starting one week after the initial dose) for 16 weeks.
Patienterne fik tre konsekutive doser under fastende betingelser eller efter et fedt- og kalorierigt måltid (46 g fedt, 1.091 kcal), hvor AUC0-12, Cmax og Ctrough værdier af saquinavir under fastende betingelser var omkring 70 % lavere end efter et måltid med højt fedtindhold.
1000 mg/100 mg twice daily and receiving three consecutive doses under fasting conditions or after a high-fat, high-calorie meal (46 g fat, 1,091 Kcal), the AUC0-12, Cmax and Ctrough values of saquinavir under fasting conditions were about 70 per cent lower than with a high-fat meal.
Patienterne fik velaglucerase alfa i doser fra 30 til 60 enheder/kg (mediandosis var
Patients received doses ranging from 30 to 60 Units/kg (median dose
Patienterne fik Vimpat i doser på 200 mg, 400 mg, 600 mg dagligt eller placebo ud over den igangværende behandling med op til tre andre antiepileptiske lægemidler.
Patients added Vimpat at a dose of 200 mg, 400 mg or 600 mg a day, or placebo to their existing treatment of up to three other anti-epileptic medicines.
Patienterne forblev ADA- positive under behandlingsfasen og opfølgningen.
The patients remained ADA positive during treatment phase and follow-up.
Patienterne fortsatte på faste doser NSAID og/eller prednison (≤ 0,2 mg/kg/dag eller maksimalt
Patients remained on stable doses of NSAIDs and or prednisone ( 0.2 mg /kg/day or 10 mg/day maximum).
Patienterne forventes på diagnosetidspunktet at have nogen grad af nedsat leverfunktion, som forbedres under behandling med cholsyre.
Patients are expected to present with some degree of hepatic impairment at diagnosis, which improves under cholic acid therapy.
Patienterne får om nødvendigt også andre lægemidler for at mindske risikoen for udvikling af infusionsreaktioner og andre bivirkninger.
Patients may also be given other medicines to prevent infusion-related reactions and other side effects.
Patienterne gav i deres rapportering om brugervenlighed og generel tilfredshed med behandlingen (indsamlet via et spørgeskema med patientrapporterede resultater), konsekvent udtryk for større tilfredshed med TOBI Podhaler sammenlignet med tobramycin, inhalationsvæske til nebulisator, opløsning, i hver cyklus.
Patient- reported convenience and overall treatment satisfaction (as collected through a patient-reported outcomes questionnaire) were consistently higher with TOBI Podhaler compared with tobramycin nebuliser solution in each cycle.
Patienterne gennemsnitsalder i studiet var 57 år, 55 % var mænd, og 48 % af patienterne blev cytogenetisk klassificeret som højrisiko.
Median age of the patients in the study was 57 years, 55% were male and 48% of patients had high-risk cytogenetics.
Patienterne har udviklet alvorlige kutanreaktioner, herunder Stevens-Johnsons syndrom (ikke almindelig), toksisk epidermal nekrolyse (sjælden) og erythema multiforme (sjælden) under behandling med VFEND.
Patients have developed serious cutaneous reactions, including Stevens-Johnson syndrome (uncommon), toxic epidermal necrolysis (rare) and erythema multiforme (rare) during treatment with VFEND.
Patienterne har udviklet alvorlige kutanreaktioner, herunder Stevens-Johnsons syndrom (ikke almindelig), toksisk epidermal nekrolyse (sjælden) og erythema multiforme (sjælden) under behandling med voriconazol.
Patients have developed serious cutaneous reactions, including Stevens-Johnson syndrome (uncommon), toxic epidermal necrolysis (rare) and erythema multiforme (rare) during treatment with voriconazole.
Patienterne har udviklet alvorlige kutanreaktioner, herunder Stevens-Johnsons syndrom (ikke-almindelig), toksisk epidermal nekrolyse (sjælden) og erythema multiforme (sjælden) under behandling med voriconazol.
Patients have developed serious cutaneous reactions, including Stevens-Johnson syndrome (uncommon), toxic epidermal necrolysis (rare) and erythema multiforme (rare) during treatment with voriconazole.
Patienterne havde aktiv SLE-sygdom, defineret ved en SELENA-SLEDAI-score på  6 (SELENA = Safety of Estrogens in Systemic Lupus Erythematosus National Assessment og SLEDAI = Systemic Lupus Erythematosus Disease Activity Index) og positive resultater for antinukleært-antistof (ANA) (ANA-titer  1:80 og/eller positiv anti-dsDNA [ 30 enheder/ml]) ved screeningen.
Patients had active SLE disease, defined as a SELENA-SLEDAI (SELENA=Safety of Estrogens in Systemic Lupus Erythematosus National Assessment; SLEDAI=Systemic Lupus Erythematosus Disease Activity Index) score 6 and positive anti-nuclear antibody (ANA) test results (ANA titre 1:80 and/or a positive anti-dsDNA [30 units/ml]) at screening.
Patienterne havde EDSS 0-3,0, mindst 2 MS-attakker i løbet af de forudgående 2 år og ≥ 1 gadoliniumforstærket læsion ved studiestart.
Patients had an EDSS from 0-3.0, at least 2 clinical episodes of MS in the prior 2 years, and ≥1 gadolinium-enhancing lesion at study entry.
Patienterne havde en anamnese med kroniske ikke- cancersmerter og tog opioider i stabile doser svarende til mindst 50 mg oral morfin om dagen.
Patients had a history of chronic non-cancer pain and were taking opioids with stable doses of at least 50 mg of oral morphine equivalents per day.
Patienterne havde en gennemsnitlig alder på 42 år (interval 19-73), 88 % var mænd, 77 % var hvide og 17 % var sorte.
Patients had a mean age of 42 years (range 19-73), 88% were male, 77% were White, and 17% were Black.
Patienterne havde en gennemsnitsalder på 42 år (interval 19-73), 88% var mænd, 77% var hvide, 17% var sorte, og 17% var latinamerikanere.
Patients had a mean age of 42 years (range 19-73), 88% were male, 77% were White, 17% were Black, and 17% were Hispanic/Latino.
Patienterne havde en gennemsnitsalder på 45 år (18- 80 år, heraf 10 % ≥ 65 år), 66 % var kvinder, 86 % var hvide, 12 % var sorte, og 27 % var af latinamerikansk oprindelse.
Overall, patients had a mean age of 45 years (range 18-80 years with 10% at least 65 years of age or older), 66% female, 86% white, 12% black, and 27% Hispanic.
Patienterne havde et BMI ≥ 30 kg/m2 eller BMI > 27 kg/m2 med hypertension og/eller dyslipaedimia ved inklusionen.
Patients had a BMI 30 kg/m² or BMI>27 kg/m² with hypertension and/or dyslipidemia at inclusion.
Patienterne havde et eosinofiltal i blodet på  150/l ved baseline eller et eosinofiltal i blodet på ≥ 300 celler/μl i de forudgående 12 måneder før screeningen.
Patients had a blood eosinophil count of 150/L at baseline or a blood eosinophil count of 300/L in the 12 months prior to screening.
Patienterne havde et gennemsnitligt CTP-tal på 8,59 ved baseline, og 26% af patienterne var i CTP- klasse C. Det gennemsnitlige score for Model for End Stage Liver Disease (MELD) ved baseline var 16,23.
At baseline, patients had a mean CTP score of 8.59 and 26% of patients were CTP class C. The mean baseline Model for End Stage Liver Disease (MELD) score was
Patienterne havde gennemgået to eller flere behandlingsforløb med platinbaseret kemoterapi og havde haft varig virkning (ingen fremskriden af kræften i mindst 6 måneder) før det sidste behandlingsforløb.
Patients had undergone treatment with two or more regimens of platinum-based chemotherapy, and they had had a durable response (the cancer had not progressed for at least 6 months) before the last regimen.
Patienterne havde haft mindst to attakker inden for de foregående to år.
The patients had experienced at least two relapses in the previous two years.
Patienterne havde i gennemsnit tidligere modtaget 14 måneders IFN-behandling med doser ≥2 x 106 IE/uge og var alle i sen kronisk fase med en gennemsnitlig tid siden diagnose på 32 måneder.
Patients had received a median of 14 months of prior IFN therapy at doses ≥ 25 x 106 IU/week and were all in late chronic phase, with a median time from diagnosis of 32 months.
Patienterne havde i gennemsnit tidligere modtaget 14 måneders IFN-behandling med doser 25 x 106 IU/uge og var alle i sen kronisk fase med en gennemsnitlig tid siden diagnose på 32 måneder.
Patients had received a median of 14 months of prior IFN therapy at doses  25 x 106 IU/week and were all in late chronic phase, with a median time from diagnosis of 32 months.
Patienterne havde IgG/IgA/lette kæder af myelomer i henholdsvis 63 %/25 %/8 % tilfælde, mediant hæmoglobin på 105 g/l og mediant trombocyttal på 221,5 x 109/l.
Patients had IgG/IgA/Light chain myeloma in 63%/25%/8% instances, a median hemoglobin of 105 g/l, and a median platelet count of 221.5 x 109/l.
Patienterne havde ikke tidligere været i behandling med lopinavir/ritonvir.
Patients had not been on prior lopinavir/ritonavir therapy.
Patienterne havde klinisk typiske, synlige, adskilte, ikke-hyperkeratotiske, ikke-hypertrofiske AK-læsioner inden for et sammenhængende 25 cm2 stort behandlingsområde på en ikke behåret hovedbund eller i ansigtet.
Patients had clinically typical, visible, discrete, nonhyperkeratotic, nonhypertrophic AK lesions on the balding scalp or face within a contiguous 25 cm2 treatment area.
Patienterne havde mindst én ekstra risikofaktor for koronar hjertelidelse, inklusive: tidligere myokardie infarkt eller slagtilfælde (> 6 måneder før inkludering) eller dokumenteret anden aterosklerotisk kardiovaskulær sygdom (tilsammen 51,5 %), type 2 diabetes (36,1 %), høj-densitet-lipoprotein – kolesterol < 35 mg/dl eller < 0,906 mmol/l (11,6 %), venstresidig ventrikulær hypertrofi diagnosticeret ved elektrokardiogram eller ekkokardiografi (20,9 %), aktiv rygning (21,9 %).
The patients had at least one additional coronary heart disease risk factor, including: previous myocardial infarction or stroke (>6 months prior to enrollment) or documentation of other atherosclerotic cardiovascular disease (overall 51.5%), type 2 diabetes (36.1%), high density lipoprotein - cholesterol <35 mg/dl or <0.906 mmol/l (11.6%), left ventricular hypertrophy diagnosed by electrocardiogram or echocardiography (20.9%), current cigarette smoking (21.9%).
Patienterne havde også plaque psoriasis med et læsionsmål på  2 cm i diameter.
Patients also had plaque psoriasis with a qualifying target lesion  2 cm in diameter.
Patienterne havde positiv PD-L1-ekspression (tumour proportion score [TPS]  1% baseret på PD-L1 IHC 22C3 pharmDxTM-analysen).
Patients had positive PD-L1 expression (tumour proportion score [TPS]  1% based on the PD-L1 IHC 22C3 pharmDxTM Kit).
Patienterne havde primær pulmonal hypertension (10 patienter) eller pulmonal arteriel hypertension relateret til kongenit hjertesygdom (9 patienter) og var i WHO-funktionsklasse II (n=15 patienter, 79%) eller III (n=4 patienter, 21%) ved baseline.
Patients had primary pulmonary hypertension (10 patients) or pulmonary arterial hypertension related to congenital heart diseases (9 patients) and were in WHO functional class II (n = 15 patients, 79%) or class III (n = 4 patients, 21%) at baseline.
Patienterne havde refraktær sygdom eller recidiv efter mindst én tidligere ITP-behandling med trombocyttal <30.000/µl.
Subjects were refractory or relapsed to at least one prior ITP therapy with a platelet count < 30,000/µl (n=67).
Patienterne havde tidligere fået anden hiv-medicin i mindst seks måneder, men medicinens virkning var ophørt.
The patients had previously taken other treatments for HIV for at least six months, but these had stopped working.
Patienterne i BDx-gruppen fik 4 cyklusser af 21-dages varihed, hver bestående af bortezomib (1,3 mg/m2 administreret intravenøst 2 gange om ugen dag 1, 4, 8 og 11) og oralt dexamethason (40 mg/dag på dag 1-4 og dag 9-12 i cyklus 1 og 2 og på dag 1-4 i cyklus 3 og 4).
Patients in the BDx group received four 21 day cycles, each consisting of bortezomib (1.3 mg/m2 administered intravenously twice weekly on days 1, 4, 8, and 11), and oral dexamethasone (40 mg/day on days 1 to 4 and days 9 to 12, in Cycles 1 and 2, and on days 1 to 4 in Cycles 3 and 4).
Patienterne i BR-CAP-gruppen fik bortezomib (1,3 mg/m2 på dag 1, 4, 8, 11, pause dag 12-21), rituximab 375 mg/m2 i.v. på dag 1, cyclophosphamid 750 mg/m2 i.v. på dag 1, doxorubicin 50 mg/m2 i.v. på dag 1 og prednison 100 mg/m2 oralt på dag 1 til og med dag 5 i bortezomib-behandlingscyklussens 21 dage.
Patients in the BR-CAP treatment arm received bortezomib (1.3 mg/m2; on days 1, 4, 8, 11, rest period days 12-21), rituximab 375 mg/m2 IV on day 1; cyclophosphamide 750 mg/m2 IV on day 1; doxorubicin 50 mg/m2 IV on day 1; and prednisone 100 mg/m2 orally on day 1 through day 5 of the 21 day bortezomib treatment cycle.
Patienterne i BTDx-gruppen fik 6 cyklusser af 4-ugers varihed hver med bortezomib (1,3 mg/m2 administreret 2 gange om ugen på dag 1, 4, 8 og 11 efterfulgt af en 17-dages pause fra dag 12-28), dexamethason (40 mg administreret oralt på dag 1-4 og dag 8-11) samt thalidomid (administreret oralt med 50 mg dagligt på dag 1-14 og forhøjet til 100 mg på dag 15-28 og derefter til 200 mg dagligt).
Patients in the BTDx group received six 4-week cycles, each consisting of bortezomib (1.3 mg/m2 administered twice weekly days 1, 4, 8, and 11, followed by a 17-day rest period from day 12 to day 28), dexamethasone (40 mg administered orally on days 1 to 4 and days 8 to 11), and thalidomide (administered orally at 50 mg daily on days 1-14, increased to 100 mg on days 15-28 and thereafter to 200 mg daily).
Patienterne i Cimzia+MTX-gruppen havde større reduktion fra baseline i DAS28(ESR) sammenlignet med placebo+MTX-gruppen, hvilket blev observeret så tidligt som fra uge 2 og fortsatte til og med uge 52 (p<0,001 ved hvert besøg).
Patients in the Cimzia+MTX group had a greater reduction from baseline in DAS 28 (ESR) compared with the placebo+MTX group observed as early as Week 2 and continued through Week 52 (p<0.001 at each visit).
Patienterne i daclatasvir behandlingsgruppen, som ikke havde ikke- detekterbart HCV-RNA ved hverken uge 4 og 12 og alle placebo-behandlede patienter fortsatte med pegIFN/RBV i yderligere 24 uger.
Patients in the daclatasvir treatment group who did not have HCV RNA undetectable at both Weeks 4 and 12 and all placebo-treated patients continued pegIFN/RBV for another 24 weeks.